Crinetics Pharmaceuticals, Inc. (CRNX) · Aug 14, 2026 · Acquisition
Antitrust cleared — HSR waiting period expired; Austria, Germany and Australia approvals received
Regulatory approvals advance Vertex’s planned Crinetics acquisition, but the filing mostly confirms an expected path rather than creating new value.
The merger clears its main regulatory checkpoint, but this is confirmation—not a surprise. The HSR waiting period expired on August 12, 2026, and required approvals in Austria, Germany and Australia were received by August 13, 2026, subject to Australia’s waiting period expiring on August 27. 〔0〕 Because the Vertex acquisition was already announced on July 6, the transaction’s direction was known; the new information is that the regulatory process is progressing without a disclosed obstacle. (Item 8.01)
The remaining path is now narrower, with shareholder approval as the key named condition. Crinetics still requires shareholder adoption at the special meeting scheduled for August 28, 2026, alongside the remaining closing conditions. 〔1〕 (Merger approval conditions)
The expected closing timeline is unchanged rather than accelerated. Assuming shareholder approval, the companies still expect the transaction to close in early September 2026. 〔2〕 Against the market’s standing expectation that an announced deal would seek routine antitrust clearance, this is an on-track update with neutral incremental information—not a clean positive surprise.
Crinetics shareholder vote, August 28
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!